Intrahepatic Cholangiocarcinoma Pipeline Analysis

According to DelveInsight, over 18 leading companies are actively engaged in the development of more than 20 therapeutic candidates for the treatment of intrahepatic cholangiocarcinoma.

Intrahepatic Cholangiocarcinoma Overview:

Intrahepatic cholangiocarcinoma (ICC) is the second most common type of liver cancer, representing around 10% of all cholangiocarcinomas. It arises from the peripheral bile ducts located within the liver tissue, near the secondary biliary branches. Most ICC cases are histologically identified as well-differentiated adenocarcinomas. The development of ICC is frequently associated with genetic alterations, particularly activating mutations in the KRAS oncogene, which promotes cell growth, and the loss of function in the p53 tumor suppressor gene. The American Joint Committee on Cancer (AJCC) TNM staging system—currently in its seventh edition—is the standard framework for evaluating disease progression and surgical resectability, dividing ICC into four distinct stages.

Request for a detailed insights report on Intrahepatic Cholangiocarcinoma pipeline insights

“Intrahepatic Cholangiocarcinoma Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Intrahepatic Cholangiocarcinoma Therapeutics Market.

Key Takeaways from the Intrahepatic Cholangiocarcinoma Pipeline Report

• DelveInsight’s Intrahepatic Cholangiocarcinoma pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Intrahepatic Cholangiocarcinoma treatment.

• In January 2022, the US FDA approved the Investigational New Drug (IND) application for KIN-3248, a next-generation pan-FGFR inhibitor being developed by Kinnate Biopharma for intrahepatic cholangiocarcinoma.

• In February 2022, HUTCHMED launched a Phase Ib/II study in China to evaluate HMPL-453 in combination with chemotherapy or Toripalimab for advanced solid tumors, including intrahepatic cholangiocarcinoma. HMPL-453 is also being tested as a monotherapy in a Phase II clinical trial in China.

• In May 2021, Kinnate Biopharma Inc. secured USD 35 million in Series A financing to establish a joint venture in China. The venture aims to advance the development of KIN-3248 for the Chinese market. KIN-3248 is an FGFR inhibitor candidate designed to treat patients with intrahepatic cholangiocarcinoma (ICC).

• Key Intrahepatic Cholangiocarcinoma companies such as Basilea Pharmaceutica, Virogin Biotech Ltd, TriSalus Life Sciences, Forma Therapeutics, Inc, Kinnate Biopharma, Relay Therapeutics, ABL Bio, Hutchison MediPharma, Sirnaomics, Jiangsu Hengrui Medicine, and others are evaluating new drugs for Intrahepatic Cholangiocarcinoma to improve the treatment landscape.

• Promising Intrahepatic Cholangiocarcinoma pipeline therapies in various stages of development include Derazantinib, and others.

Intrahepatic Cholangiocarcinoma Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Intrahepatic Cholangiocarcinoma Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Intrahepatic Cholangiocarcinoma treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Intrahepatic Cholangiocarcinoma market.

Download our free sample page report on Intrahepatic Cholangiocarcinoma pipeline insights

Intrahepatic Cholangiocarcinoma Emerging Drugs

• Derazantinib: Basilea Pharmaceutica

Intrahepatic Cholangiocarcinoma Companies

More than 18 prominent companies are actively developing treatments for intrahepatic cholangiocarcinoma. Among these, Basilea Pharmaceutica stands out with its drug candidates being the furthest along in development, currently in Phase II clinical trials.

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Intrahepatic Cholangiocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Intrahepatic Cholangiocarcinoma Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Intrahepatic Cholangiocarcinoma Therapies and Key Companies: Intrahepatic Cholangiocarcinoma Clinical Trials and advancements

Intrahepatic Cholangiocarcinoma Pipeline Therapeutic Assessment

• Intrahepatic Cholangiocarcinoma Assessment by Product Type

• Intrahepatic Cholangiocarcinoma By Stage

• Intrahepatic Cholangiocarcinoma Assessment by Route of Administration

• Intrahepatic Cholangiocarcinoma Assessment by Molecule Type

Download Intrahepatic Cholangiocarcinoma Sample report to know in detail about the Intrahepatic Cholangiocarcinoma treatment market @ Intrahepatic Cholangiocarcinoma Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Intrahepatic Cholangiocarcinoma Current Treatment Patterns

4. Intrahepatic Cholangiocarcinoma – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Intrahepatic Cholangiocarcinoma Late-Stage Products (Phase-III)

7. Intrahepatic Cholangiocarcinoma Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Intrahepatic Cholangiocarcinoma Discontinued Products

13. Intrahepatic Cholangiocarcinoma Product Profiles

14. Intrahepatic Cholangiocarcinoma Key Companies

15. Intrahepatic Cholangiocarcinoma Key Products

16. Dormant and Discontinued Products

17. Intrahepatic Cholangiocarcinoma Unmet Needs

18. Intrahepatic Cholangiocarcinoma Future Perspectives

19. Intrahepatic Cholangiocarcinoma Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Intrahepatic Cholangiocarcinoma Pipeline Reports Offerings

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/